 Todos Medical Ltd has announced an update regarding the ongoing clinical development of Tollovir, its oral antiviral 3CL protease inhibitor and anti-cytokine therapeutic candidate to treat coronavirus COVID-19. The company said enrollment of the 77-patient, Phase 2, randomized, double-blind, placebo-controlled clinical trial in hospitalized COVID-19 patients has been paused at the two open clinical sites in Israel -- Shaare Zedek Medical Center in Jerusalem and Hillel Yaffe Medical Center in Hadera -- to allow for an interim analysis of the data. 